This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Psychiatry, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Gen Psychiatry. 2000;57:321-322.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

NEW MEDICINES for which a manufacturer seeks market approval are usually tested against placebo, irrespective of whether effective treatment already exists for the condition. This is a requirement set forth by the US Food and Drug Administration (FDA).¹ The FDA maintains that placebo-controlled trials are necessary for an easy comparison of the new drug with "nothing," whereas evaluating therapeutic equivalence of a new vs an old medication is more problematic.² Many patients in clinical trials are therefore deprived of effective medications. A few years ago, my colleague Ken Rothman and I drew attention to this unethical use of placebo controls.³ If effective therapy exists, the physician has an ethical and legal obligation to provide it to the patient according to ethical standards that are laid out in the Declaration of Helsinki.⁴ The Declaration of Helsinki mandates that a new drug be compared with the best available treatment, thus placing the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials: An Analysis of the Food and Drug Administration Database
Arif Khan, Heather A. Warner, and Walter A. Brown
Arch Gen Psychiatry. 2000;57(4):311-317.
ABSTRACT | FULL TEXT  

Placebo Controls: No News Is Good News
Paul Leber
Arch Gen Psychiatry. 2000;57(4):319-320.
EXTRACT | FULL TEXT  

What Conditions Are Necessary to Assess Antidepressant Efficacy?
Frederic M. Quitkin and Donald F. Klein
Arch Gen Psychiatry. 2000;57(4):323-324.
EXTRACT | FULL TEXT  

Suicide and Antidepressant Treatment
Robert M. A. Hirschfeld
Arch Gen Psychiatry. 2000;57(4):325-326.
EXTRACT | FULL TEXT  

Statistical Analysis to Settle Ethical Issues?
Helena Chmura Kraemer
Arch Gen Psychiatry. 2000;57(4):327-328.
EXTRACT | FULL TEXT  

Placebo Protects Subjects From Nonresponse: A Paradox of Power
Andrew C. Leon
Arch Gen Psychiatry. 2000;57(4):329-330.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ethical aspects of placebo groups in pain trials: Lessons from psychiatry
Nagasako and Kalauokalani
Neurology 2005;65:S59-S65.
ABSTRACT | FULL TEXT  

Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh et al.
JAMA 2002;287:1840-1847.
ABSTRACT | FULL TEXT  

The Undiscovered Mind: How the Human Brain Defies Replication, Medication, and Explanation
FORREST
Am. J. Psychiatry 2002;159:333-334.
FULL TEXT  

Pharmacologic Treatment of Traumatized Children
COHEN
Trauma Violence Abuse 2001;2:155-171.
ABSTRACT